Compare UBCP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | ATYR |
|---|---|---|
| Founded | 1902 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.1M | 72.6M |
| IPO Year | N/A | 2015 |
| Metric | UBCP | ATYR |
|---|---|---|
| Price | $13.25 | $0.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 3.3K | ★ 3.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | $190,000.00 |
| Revenue This Year | N/A | $420.85 |
| Revenue Next Year | $5.59 | $1,513.40 |
| P/E Ratio | $10.24 | ★ N/A |
| Revenue Growth | ★ 4.40 | N/A |
| 52 Week Low | $12.25 | $0.64 |
| 52 Week High | $15.64 | $7.29 |
| Indicator | UBCP | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 48.30 |
| Support Level | $13.21 | $0.70 |
| Resistance Level | $13.40 | $0.81 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 100.00 | 85.52 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.